Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 62Other hematologic neoplasm 16Plasma cell 4Dermatologic 2Sarcoma 1Head & Neck 1CNS 1

Conditions

Multiple Myeloma 430Neoplasms, Plasma Cell 58Recurrence 33Smoldering Multiple Myeloma 17Neoplasms 14Hematologic Diseases 11Immunoglobulin Light-chain Amyloidosis 8Leukemia, Plasma Cell 7Paraproteinemias 6Hematologic Neoplasms 6Amyloidosis 6Neoplasm, Residual 5Renal Insufficiency 4Plasmacytoma 4Lymphoma 4Disease Progression 4Disease 4Blood Protein Disorders 4Lymphoma, Non-Hodgkin 3POEMS Syndrome 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Corneal Diseases 2Bone Marrow Neoplasms 2Wilms Tumor 1Vitamin D Deficiency 1Vascular Diseases 1

Interventions

Cyclophosphamide 69fludarabine phosphate 63Busulfan 45Peripheral Blood Stem Cell Transplantation 42Tacrolimus 40Mycophenolic Acid 37Filgrastim 35Antilymphocyte Serum 35fludarabine 31Cyclosporine 30Radiotherapy 29Melphalan 29Whole-Body Irradiation 27Methotrexate 24Etoposide 20Cord Blood Stem Cell Transplantation 18Biopsy 18Methylprednisolone 16Specimen Handling 15Rituximab 14Magnetic Resonance Spectroscopy 13Alemtuzumab 12Stem Cell Transplantation 11Granulocyte Colony-Stimulating Factor 11Cytarabine 11sargramostim 9Sirolimus 9Prednisone 9Dexamethasone 9plerixafor 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma × Lenalidomide × Plasma cell × Clear all
NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed
646 enrolled 16 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Keymed Biosciences Co.Ltd

Phase 1 Unknown
87 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01750762 2017-04-18

Lenalidomide After Allo Transplant

Dana-Farber Cancer Institute

Phase 1 Terminated
1 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡